|drug1170||Electronic Health Record Review Wiki||1.00|
|drug498||Biospecimen Collection Wiki||0.58|
|drug2742||Questionnaire Administration Wiki||0.38|
|D003141||Communicable Diseases NIH||0.08|
There is one clinical trial.
Plasma from patients who have recovered from coronavirus disease 2019 (COVID-19) is referred to as COVID-19 convalescent plasma (CCP), and may contain antibodies against SARS-CoV-2, the virus responsible for COVID-19. CCP infusion is being evaluated as a therapeutic or prophylactic approach in COVID-19 patients. The goal of this study is to help develop a bank of convalescent plasma in California, especially in medically underserved communities particularly affected by the disease. In parallel, CCP administered to COVID-19 patients will be collected and analyzed to determine whether the antibody profile correlates with clinical outcome. The purpose of this non-therapeutic study is to learn more about the CCP antibody profile and the effect it may have in treating COVID-19 infection.
Description: Will be assayed for severe acute respiratory syndrome (SARS-CoV-2) immunoassay, coronavirus (CoV) PepSeq assay, and SARS-CoV-2 lenti-based neutralizing antibody titer.Measure: Convalescent plasma (CCP) units infused in coronavirus disease-2019 (COVID-19) patients Time: Up to 12 months after enrollment
Description: Will naturally be compared to reported data from the other studies. Analysis will focus on demonstrating that the antibody content of donor plasma increases the odds of surviving past day 28. Will also develop a nomogram for the probability of success (alive at day 28), accounting for patient, donor material and donor antibody characteristics measurable covariates.Measure: All-cause mortality Time: At day 28 post-CCP infusion
Description: Will be examined to see how this relates to the duration of hospitalization.Measure: Donor antibody levels Time: Up to 28 days post-CCP infusion
Description: Will be assessed on a 7-point ordinal scale, as recommended by the WHO patient outcome R&D Blueprint Group.Measure: Incidence of adverse events Time: Up to 28 days post-CCP infusion
Description: Will be assessed on a 7-point ordinal scale. The scale is as follows: Death; Hospitalized, on invasive mechanical ventilation or ECMO; Hospitalized, on non-invasive ventilation or high flow oxygen devices; Hospitalized, requiring low flow supplemental oxygen; Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care (other than per protocol RDV administration); Not hospitalizedMeasure: CCP recipient outcomes Time: Up to 28 days post-CCP infusion
Description: Patient can stay at the hospital for up to 28 days post-CCP infusionMeasure: Duration of hospitalization (days) Time: Up to 28 days post-CCP infusion
Description: Will be assessed on a 7-point ordinal scale.Measure: Time to clinical improvement (days) Time: Up to 28 days post-CCP infusion
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports